A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/08/2011	US20110300150 Compositions and methods for treatment of autoimmune and other disease
12/08/2011	US20110300149 Ljungan virus
12/08/2011	US20110300142 Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
12/08/2011	US20110300137 Use of lumefantrine and related compounds in the treatment of cancer
12/08/2011	US20110300132 4-aminoquinazoline prodrugs
12/08/2011	US20110300128 Use of foxp2 as a marker for abnormal lymphocytes and as a target for therapy of disorders associated with abnormal lymphocytes
12/08/2011	US20110300125 Compositions and methods for combined therapy of disease
12/08/2011	US20110300115 Use of inductor agents gse24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence
12/08/2011	US20110300113 Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro
12/08/2011	US20110300107 Compositions and Methods to Treat Cardiac Pacing Conditions
12/08/2011	US20110300104 Hepatitis c virus inhibitors
12/08/2011	US20110300103 Heterocyclic antiviral compounds
12/08/2011	US20110300095 Malodor neutralizing compositions comprising undecylenic acid or citric acid
12/08/2011	US20110300093 Cosmetic composition containing an amphiphilic zwitterionic copolymer
12/08/2011	US20110300086 Film-Forming Solutions Comprising Vitamin D or Derivative Thereof and a Corticosteroid and Dermatological Applications Thereof
12/08/2011	US20110300083 Personal care formulations containing alkyl ketal esters and methods of manufacture
12/08/2011	US20110300081 Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same)
12/08/2011	US20110300079 Compositions for use with a system for improved cooling of subcutaneous lipid-rich tissue
12/08/2011	US20110300074 3,6-disubstituted xanthylium salts
12/08/2011	DE102011013341A1 New water-soluble or water swellable polymer comprising amidoalkyl sulfonic-, alkylamide- and crosslinked alkyleneoxy-repeating units, useful e.g. as a thickener, emulsifier, sensory additives, solubilizer, dispersant and lubricant
12/08/2011	DE102010022937A1 Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung Cell-specific activatable biologically active molecules on the basis of siRNA, methods for their activation and application kit for administering
12/08/2011	DE102010022567A1 Zubereitung Preparation
12/08/2011	CA2837818A1 Methods and compositions for treating a subject for central nervous system (cns) injury
12/08/2011	CA2805270A1 Treatment of inflammatory disorders
12/08/2011	CA2801801A1 Novel pharmaceutical compounds
12/08/2011	CA2801770A1 Methods of treatment
12/08/2011	CA2801645A1 Methods of treatment of pancreatic cancer
12/08/2011	CA2801597A1 New compounds for the prevention and/or treatment of osteoarthrosis
12/08/2011	CA2801535A1 Composition and method for inner ear sensory hair cell regeneration or replacement
12/08/2011	CA2801491A1 C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
12/08/2011	CA2801487A1 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
12/08/2011	CA2801454A1 Nitrate and diazeniumdiolate derivatives of pioglitazone
12/08/2011	CA2801449A1 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
12/08/2011	CA2801448A1 Cancer treatment with wortmannin analogs
12/08/2011	CA2801426A1 Combination cancer therapies with wortmannin analogs
12/08/2011	CA2801417A1 Optically active dibenzylamine derivative, and method for preparing thereof
12/08/2011	CA2801405A1 Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
12/08/2011	CA2801342A1 Regulation of metabolism by mir-378
12/08/2011	CA2801314A1 Methods of treating bladder cancer
12/08/2011	CA2801309A1 Methods and compositions for oral pharmaceutical therapy
12/08/2011	CA2801292A1 Oral formulations of bipolar trans carotenoids
12/08/2011	CA2801274A1 Compounds for the treatment of clostridium difficile associated disease
12/08/2011	CA2801226A1 Processes for the preparation of dipyridamole
12/08/2011	CA2801145A1 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
12/08/2011	CA2801074A1 Glycine transporter-1 inhibitors, methods of making them, and uses thereof
12/08/2011	CA2801066A1 Compositions and methods directed to treating liver fibrosis
12/08/2011	CA2801061A1 Benzoquinolone inhibitors of vmat2
12/08/2011	CA2801031A1 Substituted imidazopyrazines
12/08/2011	CA2801030A1 Crystal of thienopyrimidine derivative
12/08/2011	CA2801003A1 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
12/08/2011	CA2801001A1 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
12/08/2011	CA2800913A1 The use of inhibitors of bruton's tyrosine kinase (btk)
12/08/2011	CA2800900A1 Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
12/08/2011	CA2800747A1 Rhenium complexes and their pharmaceutical use
12/08/2011	CA2800730A1 Mitochondrial penetrating peptides as carriers for antimicrobials
12/08/2011	CA2800668A1 New forms of rifaximin and uses thereof
12/08/2011	CA2800664A1 Cytochrome p450 inhibitors and uses thereof
12/08/2011	CA2800523A1 Purinone derivative
12/08/2011	CA2800417A1 A pharmaceutical composition for topical application comprising a mitogenic agent in combination with one or more bactericidal and bacteriostatic agents
12/08/2011	CA2800401A1 Biodegradable lipids for the delivery of active agents
12/08/2011	CA2800279A1 Oral dosage forms of bendamustine
12/08/2011	CA2800277A1 Oral dosage forms of bendamustine and therapeutic use thereof
12/08/2011	CA2799972A1 Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
12/08/2011	CA2799817A1 Inhibitors of jnk
12/08/2011	CA2799653A1 Substituted isoquinolines and their use as tubulin polymerization inhibitors
12/08/2011	CA2799328A1 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
12/08/2011	CA2798239A1 Malodor neutralizing compositions comprising undecylenic acid or citric acid
12/08/2011	CA2798090A1 Pharmaceutical compositions of co-crystals of tramadol and coxibs
12/08/2011	CA2796620A1 Injectable formulation
12/07/2011	EP2392677A2 Combined use of prame inhibitors and hdac inhibitors
12/07/2011	EP2392660A2 ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor
12/07/2011	EP2392647A1 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
12/07/2011	EP2392646A1 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
12/07/2011	EP2392645A1 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
12/07/2011	EP2392594A1 N-terminally monopegylated polypeptides and process for their preparation
12/07/2011	EP2392584A1 Crystalline Ciclesonide Methanol Solvate Form C
12/07/2011	EP2392580A1 2'-fluoronucleosides
12/07/2011	EP2392579A1 Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
12/07/2011	EP2392577A1 New family of antichagasics derived from imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxide
12/07/2011	EP2392576A1 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
12/07/2011	EP2392574A1 Indolyl pyrrolidines for the treatment of cancer
12/07/2011	EP2392573A1 Quinoline derivative
12/07/2011	EP2392572A1 Substituted diazepan compounds as orexin receptor antagonists
12/07/2011	EP2392571A2 Indol-3-yl-carbonyl-piperidin and piperazin derivatives
12/07/2011	EP2392567A1 Benzothiazine derivatives and their use as lxr modulators
12/07/2011	EP2392565A1 c-Met modulators and methods of use
12/07/2011	EP2392564A1 c-Met modulators and methods of use
12/07/2011	EP2392562A1 Structural carotenoid analogs for the inhibition and amelioration of disease
12/07/2011	EP2392561A1 Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
12/07/2011	EP2392354A1 Finely pulverized pharmaceutical composition
12/07/2011	EP2392352A2 Cd93 or use of soluble fragment thereof
12/07/2011	EP2392350A1 Methods for treating conditions associated with MASP-2 dependent complement activation
12/07/2011	EP2392338A1 Prophylactic or therapeutic agent for diseases associated with abnormal bone metabolism
12/07/2011	EP2392337A2 Use of 24-norUDCA
12/07/2011	EP2392336A2 Use of 24-norUDCA
12/07/2011	EP2392335A2 Use of 24-norUDCA
12/07/2011	EP2392334A1 Nitrate esters of corticoid compounds useful as diuretics
12/07/2011	EP2392333A1 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
12/07/2011	EP2392332A1 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
12/07/2011	EP2392331A1 Nicotine-containing product

1 ... 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 ... 7860